Case series on high grade appendiceal cancer with peritoneal and liver carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors :: Roy SP
Al Zhahrani N
Barat S
Morris DL
Source :: International journal of surgery case reports [Int J Surg Case Rep] 2022 May; Vol. 94, pp. 107027. Date of Electronic Publication: 2022 Apr 04.
Publication Year :: 2022
Abstract: Background: Pseudomyxoma Peritonei (PMP) is a mucin producing cancer with appendix as primary site. Cytoreductive Surgery (CRS) combined with hyper-thermic intraperitoneal chemotherapy (HIPEC) is an established form of therapy known to prolong survival in patients with PMP and peritoneal carcinomatosis. Methods/patients In our case series, we present five cases of PMP with synchronous liver and peritoneal metastasis treated with CRS and HIPEC. It is a very rare condition which needs more research to be able to comment on overall survival.<br />Results: However, in our study, we found lower age, female gender and complete cytoreduction in surgery to be favourable predictors for improved morbidity.<br />Conclusion: In our experience, CRS/HIPEC seem to be feasible for patients with PMP with synchronous liver and peritoneal metastasis.<br /> (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Full Text Access

Tools